Keith Manchester - Myovant Sciences Director

MYOVDelisted Stock  USD 26.98  0.01  0.04%   

Director

Dr. Keith S. Manchester, M.D. is Director of Myovant Sciences Ltd. He is also a member of the board of directors of Roivant Sciences Ltd., a position he has held since May 2014, and of Arbutus Biopharma, a position he has held since March 2015. Dr. Manchester currently serves as a Managing Director and Head of Life Sciences for QVT Financial LP, an investment firm, where he was employed since 2005, and focuses on investments in both publiclytraded and privatelyowned life sciences companies. Prior to joining QVT Financial, Dr. Manchester was Vice President of Business Development from 2002 to 2004 and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, Inc., a biotechnology company. From 1999 to 2000, Dr. Manchester was an associate at Vestar Capital Partners, a private equity firm. From 1997 to 1999, Dr. Manchester was an investment banker in the healthcare group at Goldman, Sachs Co. Dr. Manchester received his A.B. degree from Harvard College and his M.D. from Harvard Medical School. since 2016.
Age 47
Tenure 8 years
Phone44 20 7400 3351
Webhttps://myovant.com

Myovant Sciences Management Efficiency

The company has return on total asset (ROA) of (0.1822) % which means that it has lost $0.1822 on every $100 spent on assets. This is way below average. Myovant Sciences' management efficiency ratios could be used to measure how well Myovant Sciences manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 358.7 M in liabilities with Debt to Equity (D/E) ratio of 138.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Myovant Sciences has a current ratio of 1.79, which is within standard range for the sector. Debt can assist Myovant Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, Myovant Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Myovant Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Myovant to invest in growth at high rates of return. When we think about Myovant Sciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Fiona KearnsRyanair Holdings PLC
N/A
Mike OBrienRyanair Holdings PLC
73
Yang WangSunlands Technology Group
45
Xiaochuan WangSunlands Technology Group
40
Richard ConnorAntero Midstream Partners
67
Michael HorganRyanair Holdings PLC
77
Robert NewellAris Water Solutions
67
Louise PhelanRyanair Holdings PLC
50
Hon LauYuexiu Transport Infrastructure
67
Howard KeenanAntero Midstream Partners
66
Zheng DuSunlands Technology Group
40
Gaoneng JiSunlands Technology Group
31
David KeyteAntero Midstream Partners
64
ConradieAris Water Solutions
N/A
Sam SunSunlands Technology Group
44
Shangning QianYuexiu Transport Infrastructure
51
John LeahyRyanair Holdings PLC
N/A
Emer DalyRyanair Holdings PLC
54
Paul KorusAntero Midstream Partners
60
ChinamoAris Water Solutions
N/A
John MollenkopfAntero Midstream Partners
58
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd. Myovant Sciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 579 people. Myovant Sciences (MYOV) is traded on New York Stock Exchange in USA and employs 579 people.

Management Performance

Myovant Sciences Leadership Team

Elected by the shareholders, the Myovant Sciences' board of directors comprises two types of representatives: Myovant Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Myovant. The board's role is to monitor Myovant Sciences' management team and ensure that shareholders' interests are well served. Myovant Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Myovant Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Frank Karbe, Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc.
Juan Ferreira, Chief Commercial Officer - Myovant Sciences, Inc
Mark Altmeyer, Independent Director
Nancy Valente, Director
Kim Sablich, Chief Commercial Officer
Adele Gulfo, Director, Interim Chief Commercial Officer
Myrtle Potter, Chairman of the Board
Terrie Curran, Independent Director
Lauren Merendino, Chief Commercial Officer
Keith Manchester, Director
Marianne Romeo, Head, Global Transactions & Risk Management
Ann Tomlin, VP HR
Juan MD, Chief Officer
Uneek Mehra, Chief Financial and Business Officer, Principal Financial and Accounting Officer
Frank Torti, Director
Andria MD, Head Pharmacovigilance
Matthew JD, Gen Sec
Vivek Ramaswamy, Director
Jeffrey Nornhold, Senior Vice President Pharmaceutical Operations & Development
Albert Liao, Director Communications
Wayne DeVeydt, Independent Director
Matthew Lang, General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc.
Kathleen Sebelius, Lead Independent Director
Mark Guinan, Independent Director
David Marek, Principal Executive Officer, Director
Hiroshi Nomura, Director
Bryan Selby, VP Devel
Lynn Seely, Principal Executive Officer, Director

Myovant Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Myovant Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Myovant Sciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Myovant Sciences' short interest history, or implied volatility extrapolated from Myovant Sciences options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Other Consideration for investing in Myovant Stock

If you are still planning to invest in Myovant Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Myovant Sciences' history and understand the potential risks before investing.
Stocks Directory
Find actively traded stocks across global markets
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.